肯尼亚的高血压固定剂量组合治疗的可接受性:使用可接受性的理论框架进行定性研究
Daniel Mbuthia1, Ruth Willis2, Mary Gichagua3
1Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
PLOS global public health
|March 18, 2025
概括
肯尼亚的患者和医护人员可以接受高血压的固定剂量组合 (FDC). 提高FDC知识和可用性是更好的高血压管理的关键.
科学领域:
- 心血管医学 心血管医学
- 公共卫生 公共卫生
- 卫生系统研究 卫生系统研究
背景情况:
- 高血压是撒哈拉以南非洲地区的重大健康负担,控制率较低.
- 固定剂量组合 (FDC) 在高血压治疗中提供了潜在的好处,但面临着实施挑战.
研究的目的:
- 探索固定剂量组合 (FDC) 在肯尼亚患者,护理人员和医疗保健工作者中用于高血压治疗的可接受性.
- 确定影响在撒哈拉以南非洲背景下FDC实施的因素.
主要方法:
- 与58名参与者进行了半结构化的深度访谈,这些访谈在肯尼亚基安布县进行.
- 数据分析采用了一种代的主题分析方法,以"可接受性理论框架"为指导.
主要成果:
- 发现FDC对所有参与者群体来说都是潜在的可接受的,因为它们被认为可以减少治疗负担并改善坚持.
- 医疗保健工作者的接受度可能受到知识差距,对不灵活性的担忧以及可用性和负担能力的问题所阻碍.
- 患者的接受性是由对医疗保健提供者的信任所支持的.
结论:
- 提高FDC的可接受性需要加强医疗保健工作者在处方,患者教育和坚持支持方面的能力.
- 解决FDC可用性和负担能力等系统性问题对于肯尼亚成功实施至关重要.
相关概念视频
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
119
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
119
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356
Antihypertensive Drugs: Direct Renin Inhibitors
466
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
466
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
124
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
124
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
37
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
37


